Tafamidis 61mg, Outcomes in ATTR Amyloidosis With Neurologic and Multisystemic Involvement - TRAMA
Latest Information Update: 16 May 2024
At a glance
- Drugs Tafamidis meglumine (Primary)
- Indications Transthyretin-related hereditary amyloidosis
- Focus Therapeutic Use
- Acronyms TRAMA
- Sponsors Pfizer
Most Recent Events
- 23 Dec 2022 Status changed from recruiting to completed.
- 01 Dec 2022 Status changed from not yet recruiting to recruiting.
- 04 Oct 2022 New trial record